Please ensure Javascript is enabled for purposes of website accessibility

2 High-Growth ETFs That Should Make You Rich Over the Next 10 Years

By Keith Speights - Mar 5, 2021 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They've both already made some investors a lot of money over the last few years.

Exchange-traded funds (ETFs) offer a simple and powerful way to buy baskets of stocks. And they come in lots of flavors. Investors can easily find an ETF that aligns with their risk tolerance.

Some of these funds are especially well-suited for aggressive investors willing to take bigger risks in their pursuit of tremendous returns. Here are two high-growth ETFs that should make you richer over the next 10 years.

ETF with letters made of $100 bills

Image source: Getty Images.

1. ARK Innovation ETF

Cathie Wood, founder and CEO of ARK Investment Management, ranks as one of the most influential investment managers in the world. She has spearheaded the formation of several successful ETFs, including her firm's largest fund, ARK Innovation ETF (ARKK 6.52%).

ARK Innovation is actively managed and typically has between 35 and 55 holdings. It focuses on companies that hold the potential to change the way the world works through disruptive innovation. So what kind of stocks meet up to that ambitious goal? Just look at some of ARKK's current top holdings.

The ETF's biggest position right now is in Tesla (TSLA 7.33%). It also owns stakes of more than $1 billion each in three other companies -- Square (SQ 8.52%), Roku (ROKU 8.96%), and Teladoc Health (TDOC 6.94%)

Those four businesses operate in entirely different markets. Tesla, of course, is a leader in electric vehicles and clean energy products. Square stands at the forefront of the fintech revolution with its payment processing platform and devices for small businesses and its Cash App peer-to-peer payments app. Roku is an industry leader in streaming TV. Teladoc Health is a pioneer in telehealth.

One thing that they all have in common, though, is that they're disruptive innovators. ARKK seeks to find similar stocks, primarily ones with a technology focus, that could be huge winners. For example, the ETF recently invested in PACCAR (NASDAQ: PCAR), which is developing autonomous trucks and trucks powered by hydrogen fuel cells.

ARKK's expense ratio is 0.75% -- more than you'll usually be charged for an index ETF. However, that premium is a small price to pay for the performance investors get. ARKK delivered an average annual return of more than 52% over the last three years and an average annual return of 36% since the ETF was launched in 2014.

Note, however, that those percentages don't reflect the steep decline in ARKK's share price on Thursday. The kinds of stocks in this ETF tend to fall harder than the overall market does in major sell-offs. Don't let that scare you off, though. With Wood continually seeking out companies that could be game-changers, this ETF should make investors who buy and hold through potential volatility a lot of money over the next decade.

2. SPDR S&P Biotech ETF

Unlike ARKK, the SPDR S&P Biotech ETF (XBI 3.83%) isn't actively managed. It's designed to track the performance of the S&P Biotechnology Select Industry Index, which includes biotech stocks that trade on U.S. exchanges.

One key hallmark of the index is that it's relatively equally weighted across all the stocks that it holds. No single stock makes up a significantly greater percentage of total assets than the others. 

The SPDR S&P Biotech ETF currently includes more than 170 stocks. A handful of those are giants such as AbbVie and Gilead Sciences. Most, though, are relatively small. That's because there are a lot more small biotechs than there are large ones.

Picking individual biotech stocks to buy can be a daunting task, especially when you're trying to evaluate companies that don't have products on the market yet. The SPDR S&P Biotech ETF gives investors an easy way to buy a basket of them. Some will be losers, but there will also likely be plenty of winners. In a real sense, buying this ETF is a bet that biotechnology, in general, will achieve significant advances.

That's been a pretty good bet to make so far. The SPDR S&P Biotech ETF has generated an average annual return of 18% over the last three years and an average annual return of more than 16% since its inception in 2006. Its expense ratio of 0.35% is also relatively low.

Can this ETF deliver performance in the future similar to what it has done over the last 15 years? There's no guarantee, but it's quite possible. If it does, an initial investment of $10,000 in the ETF now would grow to more than $44,000 over the next 10 years. Like ARKK, XBI could make investors who buy and hold a fortune over the long run.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

SPDR Series Trust - SPDR S&P Biotech ETF Stock Quote
SPDR Series Trust - SPDR S&P Biotech ETF
$71.09 (3.83%) $2.62
Tesla, Inc. Stock Quote
Tesla, Inc.
$759.63 (7.33%) $51.90
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$35.77 (6.94%) $2.32
Block, Inc. Stock Quote
Block, Inc.
$90.52 (8.52%) $7.11
Roku Stock Quote
$96.47 (8.96%) $7.93
ARK ETF Trust - ARK Innovation ETF Stock Quote
ARK ETF Trust - ARK Innovation ETF
$45.41 (6.52%) $2.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.